Federation of Italian Cooperative Oncology Groups Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2007
NCT00526643
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

APRIC/CTPG | Federation of Italian Cooperative Oncology Groups

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

exemestane (aromasin) (1 trial)

gemcitabine (gemzar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Lung Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3